Ascendis Pharma Reports Topline P-II (New InsiGHTS) Trial Data on TransCon hGH in Turner Syndrome

Why It Matters

Demonstrating comparable efficacy with a lower, once‑weekly dose could improve adherence and reshape growth‑hormone therapy for Turner syndrome, opening new market opportunities for Ascendis.

Key Takeaways

• Weekly TransCon hGH matched daily somatropin growth rates
• LS mean AHV: 9.05 vs 9.04 cm/year at week 52
• Required dose 0.22 mg/kg/week, lower than daily regimen
• Safety profile remained favorable over ~143 weeks
• P-III basket trial launched for broader indication expansion

Pulse Analysis

Growth‑hormone treatment for Turner syndrome has traditionally relied on daily injections, a regimen that can strain adherence and quality of life for young patients and their families. TransCon hGH, a prodrug delivering lonapegsomatropin on a weekly schedule, seeks to address these challenges by providing sustained hormone release while reducing injection frequency. The New InsiGHTS Phase‑II study adds to a growing body of evidence that long‑acting growth‑hormone platforms can achieve therapeutic parity with established daily products, positioning them as viable alternatives in pediatric endocrinology.

The trial’s efficacy signal—an LS mean annualized height velocity of 9.05 cm/year—mirrored the 9.04 cm/year observed with daily somatropin, despite a modestly lower weekly dose (0.22 mg/kg versus 0.29 mg/kg). This dose efficiency suggests potential cost‑benefit advantages and may translate into fewer injection‑related adverse events. Moreover, safety data collected over approximately 143 weeks showed no new concerns, reinforcing the tolerability profile that clinicians demand for long‑term pediatric therapies. Such findings are particularly compelling given the critical growth window in prepubertal children, where consistent hormone exposure is essential.

Looking ahead, Ascendis has initiated a Phase‑III basket trial, HighLiGHts, to evaluate TransCon hGH across multiple growth‑deficiency indications. Successful expansion could secure a broader label, challenging incumbents like Genentech’s somatropin and Novo Nordisk’s Norditropin. The combination of comparable efficacy, reduced dosing burden, and a strong safety record may accelerate payer acceptance and drive market share gains, reshaping the competitive dynamics of the pediatric growth‑hormone sector.